CrowdStrike Holdings Option Alert: Dec, 2026 $570 Calls Sweep (10) near the Bid: 72 vs 278 OI; Earnings 3/4 After Close 

CrowdStrike Holdings Option Alert: Dec, 2026 $570 Calls Sweep (10) near the Bid: 72 @ $69.91 vs 278 OI; Earnings 3/4 After Close Ref=$432.235

CrowdStrike Holdings Option Alert: Jan 16 $580 Calls at the Bid: 250 vs 990 OI; Earnings 3/4 After Close 

CrowdStrike Holdings Option Alert: Jan 16 $580 Calls at the Bid: 250 @ $29.85 vs 990 OI; Earnings 3/4 After Close Ref=$425.825

CrowdStrike Holdings Option Alert: Apr 17 $450 Calls Sweep (6) near the Ask: 270 vs 1606 OI; Earnings 3/4 After Close 

CrowdStrike Holdings Option Alert: Apr 17 $450 Calls Sweep (6) near the Ask: 270 @ $25.6 vs 1606 OI; Earnings 3/4 After Close Ref=$433.63

CrowdStrike Holdings Option Alert: Apr 17 $450 Calls Sweep (5) near the Bid: 303 vs 1606 OI; Earnings 3/4 After Close 

CrowdStrike Holdings Option Alert: Apr 17 $450 Calls Sweep (5) near the Bid: 303 @ $25.8 vs 1606 OI; Earnings 3/4 After Close Ref=$433.8

CrowdStrike Holdings Option Alert: Mar 21 $440 Puts at the Ask: 200 vs 38 OI; Earnings 3/4 After Close 

CrowdStrike Holdings Option Alert: Mar 21 $440 Puts at the Ask: 200 @ $25.55 vs 38 OI; Earnings 3/4 After Close Ref=$441.62

CrowdStrike Holdings 주식 (NASDAQ: CRWD)

CrowdStrike Holdings (NASDAQ:CRWD) 주식

CROWDSTRIKE HOLDINGS INC - A

CrowdStrike Holdings

CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.

Nvidia: AI Market Leader

News

CRWD

CTSH

NVDA

PLTR

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TEAM

관세로 인한 변동성 확대와 중국 딥시크의 저가 AI 모델 등장으로 인한 수요 전망 둔화가 반도체 주가에 압력을 가하고 있다. 예를 들어, 필라델피아 반도체 지수는 연초 대비 약 6% 하락했으며, 업계 선두주자인 엔비디아(NASDAQ:NVDA)는 최근 12월 고점 대비 14% 가까이 하락했다.

올해 엔비디아 주가 12% 하락...AI 투자자들, 칩에서 소프트웨어로 이동 중?

S-Link-blue-BG-1 copy

Trading Ideas

PANW

SNOW

스테파니 링크(Stephanie Link), 최고 투자 전략가인 하이타워 어드바이저스(Hightower Advisors)는 수요일에 아마존의 성장하는 지배력, 팔로알토 네트웍스(NASDAQ:PANW)의 사이버 보안 잠재력, 타깃(NYSE:TGT)의 회복 노력, 그리고 넥스테라 에너지(NYSE:NEE)의 가치 평가 기회에 대한 통찰력을 공유했다.

스테파니 링크: &#39;아마존의 시장 점유율 급증&#39; - 아마존, 팔로알토, 타깃 및 넥스테라 에너지 분석

CrowdStrikeSunnyvale,,California,Us,-,November,16,,2024:,Crowdstrike,Sign,On

Technicals

Tech

크라우드스트라이크 홀딩스(NASDAQ:CRWD)가 목요일에 애로우 일렉트로닉스(NYSE:ARW)와 팔콘(Falcon) 사이버 보안 플랫폼의 유통 계약을 체결했다고 발표했다. 투자자들은 인상적이지 않게 반응했고 주가는 금요일에도 하락세를 이어가고 있다.

오늘의 주식: 지지선을 테스트하는 크라우드스트라이크, 하락 또는 반전 가능성?

CrowdStrike Holdings, Inc. - Class A Common Stock

CrowdStrike Holdings Inc

Morgan Stanley analyst Vincent Andrews maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Equal-Weight and lowers the price target from $85 to $80.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on CF Industries Holdings, Lowers Price Target to $80

Needham analyst Gerald Pascarelli reiterates Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy and maintains $215 price target.

Reiteration

Needham Reiterates Buy on Constellation Brands, Maintains $215 Price Target

Morgan Stanley analyst Dara Mohsenian maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Equal-Weight and lowers the price target from $202 to $195.

Morgan Stanley Maintains Equal-Weight on Constellation Brands, Lowers Price Target to $195

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy

Biotech

General

AMGN

Amgen Announced Global Phase 3 DeLLphi-304 Clinical Trial Evaluating IMDELLTRA As Treatment For Patients With Small Cell Lung Cance Met Its Primary Endpoint

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) shares traded higher premarket after the company reported its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44757876/jpmorganchase-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">first-quarter&nbsp;FY24 results</a>, but they eventually gave up all the gains and traded in the red.
Reported revenue&nbsp;rose&nbsp;8%&nbsp;year-on-year (Y/Y) to&nbsp;$45.3&nbsp;billion. Net revenue (<a target="_blank" href="https://www.jpmorganchase.com/content/dam/jpmc/jpmorgan-chase-and-co/investor-relations/documents/quarterly-earnings/2025/1st-quarter/d88c408a-bbc9-4b06-b263-373f5b10b145.pdf" rel="noreferrer noopener">managed</a>) was&nbsp;$46.0 billion (+8% Y/Y), beating the&nbsp;consensus of&nbsp;$44.1 billion.
Consumer &amp; Community Banking (CCB) revenue rose&nbsp;4% Y/Y to&nbsp;$18.3&nbsp;billion, and Commercial &amp; Investment Bank (CIB) revenue was&nbsp;$19.7 billion (+12%&nbsp;Y/Y) in the quarter.
Investment Banking revenue was&nbsp;$2.3&nbsp;billion, up&nbsp;2%&nbsp;Y/Y, in the quarter. Investment Banking fees rose&nbsp;12%&nbsp;Y/Y to $2.2 billion, led by higher debt underwriting and advisory fees.
Asset and Wealth Management revenue was&nbsp;$5.73&nbsp;billion (+12% Y/Y), and Corporate revenue stood at&nbsp;$2.30&nbsp;billion (+5% Y/Y) in the quarter.
In AWM,&nbsp;Assets under management stood at&nbsp;$4.1&nbsp;trillion, and client assets stood at&nbsp;$6.0&nbsp;trillion (up&nbsp;15%), driven by higher market levels and continued net inflows.
Net interest income rose 1%&nbsp;year over year to&nbsp;$23.4 billion&nbsp;in the quarter. Net interest income excluding Markets&nbsp;stood at&nbsp;$22.6 billion, down&nbsp;2%&nbsp;year over year due to lower rates and deposit margin compression, along with lower deposit balances in CCB.&nbsp;
Noninterest revenue was&nbsp;$22.6 billion, up&nbsp;17% Y/Y, in the quarter. Noninterest revenue, excluding Markets,&nbsp;increased&nbsp;20%&nbsp;Y/Y to&nbsp;$13.8 billion.
Excluding the $588 million First Republic-related gain, noninterest revenue excluding Markets was up 14%, led by higher asset management fees in AWM and CCB, increased investment banking fees and lower net investment securities losses. Noninterest expense upped 4% Y/Y to&nbsp;$23.6&nbsp;billion&nbsp;in the quarter.
Markets revenue was $9.7 billion, up 21% Y/Y, primarily driven by higher Equity Markets revenue.
Average loans rose&nbsp;1% Y/Y and down 1%&nbsp;quarter-over-quarter (Q/Q); average deposits were down 2% Y/Y and&nbsp;flat&nbsp;Q/Q.
In CCB, Debit and credit card sales volume increased by&nbsp;7%&nbsp;year over year, and active mobile customers were up&nbsp;8% year over year. In CIB, Market revenue rose&nbsp;21%&nbsp;year over year, with Fixed-Income Markets increasing&nbsp;8%&nbsp;year over year and Equity Markets up&nbsp;48% year over year&nbsp;in the quarter.
JPM's provision for credit losses was&nbsp;$3.3 billion (+75% Y/Y), including net charge-offs of&nbsp;$2.3&nbsp;billion and a net reserve build of&nbsp;$973 million.&nbsp;
Net income rose&nbsp;9%&nbsp;Y/Y to&nbsp;$14.6&nbsp;billion in the quarter. EPS of&nbsp;$5.07 exceeded&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;$4.62</a>. The company witnessed a First Republic-related gain of $588 million in Corporate ($0.16 increase in EPS).
The CET1 capital ratio stood at&nbsp;15.4%, and the advanced CET1 capital ratio was&nbsp;15.5%. The bank's capital distributions included a dividend per share of&nbsp;$1.40 and&nbsp;$71 billion&nbsp;of common stock net repurchases.
<a target="_blank" href="https://www.jpmorganchase.com/content/dam/jpmc/jpmorgan-chase-and-co/investor-relations/documents/quarterly-earnings/2024/4th-quarter/9aff0e71-2b8c-4f41-ac93-8da74c263894.pdf" rel="noreferrer noopener">Outlook</a>: JPMorgan expects FY25 net interest income,&nbsp;excluding Markets, of ~$94.5 billion&nbsp;and project card&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">services NCO rate of ~3.60%.</a>
Jamie Dimon, Chairman and CEO, said, "In CCB, the franchise continued to acquire new customers at a robust pace, opening 500,000 net new checking accounts and adding record first-time investors in wealth management. Finally, AWM had healthy AUM net inflows of $90 billion, and investment performance remained strong."
"The economy is facing considerable turbulence (including geopolitics), with the potential positives of tax reform and deregulation and the potential negatives of tariffs and "trade wars," ongoing sticky inflation, high fiscal deficits and still rather high asset prices and volatility," he added.
Price Action: JPM shares are down 0.84%&nbsp;at&nbsp;$225.20 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44756747/us-stocks-likely-to-open-lower-as-volatility-persists-before-bank-earnings-fed-is-likely-to-cut-rates-again-on-june-18th-says-expert" target="_blank" rel="noreferrer noopener">US Stock Futures Recover After Early Dip, Poised To Open Higher Amid Volatility: ‘Fed Is Likely To Cut Rates Again On June 18th,' Says Expert</a></li>
</ul>
Image via Shutterstock

Earnings

Equities

Large Cap

Guidance

Movers

'Economy Is Facing Considerable Turbulence:' JPMorgan Chase CEO Jamie Dimon Cautions About 'Negatives Of Tariffs And Trade Wars'

WIIM

WKEY

WISeKey International shares are trading higher after the company announced that SEALCOIN demonstrated secure off-grid IoT transactions via LEO satellites and blockchain.

ADTX

Aditxt shares are trading higher after regaining Nasdaq listing requirements compliance.

BMO Capital analyst Andrew Strelzik maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Outperform and lowers the price target from $260 to $215.

BMO Capital Maintains Outperform on Constellation Brands, Lowers Price Target to $215

Orion Properties shares are trading higher after the company provided 2025 year-to-date and Q1 leasing and sales updates, including $19.1 million in vacant asset sales, 425,000 SF leased, and a $243.9 million liquidity buffer.

CORRECTION: Goldman Sachs analyst Noah Poponak downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109

Downgrades

CORRECTION: Goldman Sachs Downgrades Booz Allen Hamilton to Neutral, Lowers Price Target to $109

<a href="https://www.theinformation.com/articles/bytedance-developing-ai-smart-glasses" title="https://www.theinformation.com/articles/bytedance-developing-ai-smart-glasses">https://www.theinformation.com/articles/bytedance-developing-ai-smart-glasses</a>

ORCL

SNAP

'ByteDance Is Developing AI Smart Glasses' - The Information

Raymond James analyst David Hicks maintains Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) with a Strong Buy and lowers the price target from $66 to $55.

Raymond James Maintains Strong Buy on Knight-Swift, Lowers Price Target to $55

BLNK

Blink Charging Regains Compliance With Nasdaq's Periodic Filing Requirement

Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4403651-1&amp;h=1171470013&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Finnovative-eyewear-inc-announces-exercise-of-warrants-302236683.html%23financial-modal&amp;a=LUCY">LUCY</a>), the developer of smart eyewear under the Lucyd&#xAE;, Nautica&#xAE;, Eddie Bauer&#xAE; and Reebok&#xAE; brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 601,686 shares of the Company's common stock originally issued by the Company on September 4, 2024 and September 24, 2024, having original exercise prices of $5.00 and $9.50 per share, respectively, at a reduced exercise price of $2.60 per share. The closing of the warrant exercise transaction is expected to occur on or about April 14, 2025, subject to satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Offerings

LUCY

Innovative Eyewear Enters Into Definitive Agreements For The Immediate Exercise Of Certain Outstanding Warrants To Purchase An Aggregate Of 601,686 Shares Of The Company's Common Stock Originally Issued By The Company On September 4, 2024 And September 24, 2024, Having Original Exercise Prices Of $5.00 And $9.50 Per Share, Respectively, At A Reduced Exercise Price Of $2.60 Per Share, For $1.8M Gross Proceeds

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-35, to be effective as of 12:01 a.m. Eastern Time on April 15, 2025.
Scilex's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on April 15, 2025. Following the reverse stock split, Scilex's common stock will continue to trade on The Nasdaq Capital Market under the symbol "SCLX" with the new CUSIP number, 80880W 205. The reverse stock split is intended for Scilex to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market.
The reverse stock split will not change the authorized number of shares of Scilex's common stock. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to receive a fractional share in connection with the reverse stock split will instead receive a cash payment in lieu thereof equal to such fraction multiplied by the closing sales price of Scilex's common stock as reported on The Nasdaq Capital Market on April 14, 2025. In addition, the reverse stock split will apply to Scilex's common stock issuable (or deemed issuable, as applicable) upon the exercise or conversion, as applicable, of certain of Scilex's outstanding warrants, shares of Series A Preferred Stock, convertible notes and stock options, with proportionate adjustments to be made to the exercise and conversion prices thereof, in each case in accordance with the respective terms of such warrants, shares of Series A Preferred Stock, convertible notes and stock options (and the applicable equity incentive plans).
The reverse stock split will reduce the number of issued and outstanding shares of Scilex's common stock from approximately 243 million to approximately 6.9 million.
At Scilex's special meeting of stockholders held on March 19, 2025, Scilex's stockholders approved the reverse stock split in connection with Scilex's common stock and gave Scilex's board of directors discretionary authority to select a ratio for the reverse stock split ranging from 1-for-14 shares to 1-for-50 shares. Scilex's board of directors approved the reverse stock split at a ratio of 1-for-35 on April 3, 2025.

Stock Split

SCLX

Scilex Holding Company Announces 1-For-35 Reverse Stock Split, Effective April 15, 2025

In the latest quarter, 9 analysts provided ratings for Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.11, a high estimate of $44.00, and a low estimate of $25.00. Highlighting a 10.92% decrease, the current average has fallen from the previous average price target of $42.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1744376488_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Steven Madden by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $25.00&#x7C;$35.00 &#x7C; 
&#x7C;Laura Champine &#x7C;Loop Capital &#x7C;Lowers &#x7C;Hold &#x7C; $35.00&#x7C;$40.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $35.00&#x7C;$38.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $38.00&#x7C;$44.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $44.00&#x7C;$44.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $44.00&#x7C;$44.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $38.00&#x7C;$45.00 &#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $40.00&#x7C;$45.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $44.00&#x7C;$50.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Steven Madden. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Steven Madden compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Steven Madden's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steven Madden's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHOO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Steven Madden analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Steven Madden</h2>
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
<h3>Steven Madden: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Steven Madden showcased positive performance, achieving a revenue growth rate of 12.05% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Steven Madden's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.14%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Steven Madden's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.43% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Steven Madden adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHOO

Breaking Down Steven Madden: 9 Analysts Share Their Views

In the last three months, 11 analysts have published ratings on Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Warby Parker, presenting an average target of $24.91, a high estimate of $32.00, and a low estimate of $18.00. Experiencing a 0.36% decline, the current average is now lower than the previous average price target of $25.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744376480_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Warby Parker's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $20.00&#x7C;$30.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $18.00&#x7C;$25.00 &#x7C; 
&#x7C;Mark Carden &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $23.00&#x7C;$20.00 &#x7C; 
&#x7C;Mark Altschwager &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $32.00&#x7C;$30.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Raises &#x7C;Outperform &#x7C; $30.00&#x7C;$28.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $28.00&#x7C;$28.00 &#x7C; 
&#x7C;Matt Koranda &#x7C;Roth MKM &#x7C;Announces &#x7C;Neutral &#x7C; $26.00&#x7C;- &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $28.00&#x7C;$28.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Raises &#x7C;Sell &#x7C; $23.00&#x7C;$19.00 &#x7C; 
&#x7C;Kimberly Greenberger&#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $23.00&#x7C;$17.00 &#x7C; 
&#x7C;Mark Mahaney &#x7C;Evercore ISI Group &#x7C;Announces &#x7C;In-Line &#x7C; $23.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Warby Parker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Warby Parker compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Warby Parker's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Warby Parker's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WRBY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Warby Parker analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Warby Parker</h2>
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
<h3>Key Indicators: Warby Parker's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Warby Parker's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 17.79%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Warby Parker's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.03%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Warby Parker's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.05%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Warby Parker's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WRBY

Demystifying Warby Parker: Insights From 11 Analyst Reviews

Across the recent three months, 11 analysts have shared their insights on argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $745.36, a high estimate of $1100.00, and a low estimate of $680.00. Witnessing a positive shift, the current average has risen by 7.71% from the previous average price target of $692.00.
<img src="https://www.benzinga.com/files/images/story/2025/1744376466_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of argenx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $720.00&#x7C;$720.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $720.00&#x7C;$720.00 &#x7C; 
&#x7C;Yatin Suneja &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $1100.00&#x7C;$775.00 &#x7C; 
&#x7C;Joel Beatty &#x7C;Baird &#x7C;Raises &#x7C;Neutral &#x7C; $680.00&#x7C;$650.00 &#x7C; 
&#x7C;Leland Gershell &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $704.00&#x7C;$675.00 &#x7C; 
&#x7C;Derek Archila &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $741.00&#x7C;$723.00 &#x7C; 
&#x7C;Jason Butler &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Outperform &#x7C; $701.00&#x7C;$696.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $720.00&#x7C;$717.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $717.00&#x7C;$670.00 &#x7C; 
&#x7C;Joon Lee &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $700.00&#x7C;$660.00 &#x7C; 
&#x7C;Jason Butler &#x7C;JMP Securities &#x7C;Raises &#x7C;Market Outperform&#x7C; $696.00&#x7C;$606.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to argenx. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of argenx compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of argenx's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into argenx's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARGX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on argenx analyst ratings.</a>
<h2>Unveiling the Story Behind argenx</h2>
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
<h3>Unraveling the Financial Story of argenx</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining argenx's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 81.5% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: argenx's net margin is impressive, surpassing industry averages. With a net margin of 104.84%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 14.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 12.48%, the company showcases effective utilization of assets.
Debt Management: argenx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARGX

What 11 Analyst Ratings Have To Say About argenx

VinFast's Announces Domestic Deliveries Of Over 12,100 In Mar.

Analysts' ratings for Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Foot Locker, revealing an average target of $20.64, a high estimate of $24.00, and a low estimate of $12.00. This current average has decreased by 10.61% from the previous average price target of $23.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1744376443_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Foot Locker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $12.00&#x7C;$19.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $21.00&#x7C;$22.00 &#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $19.00&#x7C;$23.00 &#x7C; 
&#x7C;Jonathan Komp &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $20.00&#x7C;$24.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $20.00&#x7C;$24.00 &#x7C; 
&#x7C;Corey Tarlowe &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $19.00&#x7C;$22.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $24.00&#x7C;$24.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $24.00&#x7C;$24.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $24.00&#x7C;$24.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $24.00&#x7C;$25.00 &#x7C; 
&#x7C;Matthew Boss &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $20.00&#x7C;$23.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Foot Locker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Foot Locker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Foot Locker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Foot Locker analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Foot Locker: A Closer Look</h2>
Foot Locker Inc operates footwear and apparel retailer in North America, Europe, Australia, New Zealand, and Asia, and has licensed store presence in the Middle East, Europe, and Asia. The company mainly sells athletically inspired shoes and apparel. Foot Locker's merchandise comes from only a few suppliers, with Nike providing the majority. Its portfolio of brands includes Foot Locker, Kids Foot Locker, Champs Sports, WSS, and atmos. The company has omnichannel capabilities to bridge the digital world and physical stores, including order-in-store, buy online and pickup-in-store, and buy online and ship-from-store, as well as e-commerce. It has three operating segments, North America, EMEA, and Asia Pacific.
<h3>A Deep Dive into Foot Locker's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, Foot Locker faced challenges, resulting in a decline of approximately -5.7% in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Foot Locker's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Foot Locker's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Foot Locker's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.72%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Foot Locker's debt-to-equity ratio is below the industry average. With a ratio of 0.96, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
01:59 PMFeb 20, 2025	CALL	$570.00	Dec 18, 2026	615	28	72	10	278	SWEEP	BEARISH
11:28 AMFeb 20, 2025	CALL	$580.00	Jan 16, 2026	279	73	250	7	990	TRADE	BEARISH
09:39 AMFeb 20, 2025	CALL	$450.00	Apr 17, 2025	5	548	270	34	1606	SWEEP	BULLISH
09:39 AMFeb 20, 2025	CALL	$450.00	Apr 17, 2025	5	306	303	19	1606	SWEEP	BEARISH
11:20 AMFeb 13, 2025	PUT	$440.00	Mar 21, 2025	-22	209	200	550	38	TRADE	BEARISH

Comments

CrowdStrike Holdings

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌